FY2030 Earnings Forecast for KALV Issued By HC Wainwright

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for KalVista Pharmaceuticals in a research note issued on Friday, January 9th. HC Wainwright analyst A. Fein anticipates that the specialty pharmaceutical company will post earnings per share of $5.90 for the year. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million.

Several other research firms also recently issued reports on KALV. Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Citizens Jmp cut their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Finally, Needham & Company LLC raised their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $14.94 on Monday. The firm has a market cap of $755.22 million, a PE ratio of -3.78 and a beta of -0.14. The firm has a fifty day moving average of $14.76 and a 200 day moving average of $13.67. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a one year low of $7.34 and a one year high of $19.00.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of KALV. BNP Paribas Financial Markets raised its holdings in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals during the third quarter worth about $55,000. Wolverine Asset Management LLC purchased a new position in KalVista Pharmaceuticals during the third quarter worth about $57,000. KLP Kapitalforvaltning AS acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $63,000. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at approximately $81,000.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at $1,773,126.95. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the sale, the chief financial officer owned 10,529 shares of the company’s stock, valued at $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,329 shares of company stock valued at $437,371 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.